330 related articles for article (PubMed ID: 24901803)
1. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
2. Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved.
Nunez JM; Becher RD; Rebo GJ; Farrah JP; Borgerding EM; Stirparo JJ; Lauer C; Kilgo P; Miller PR
Am Surg; 2015 Jun; 81(6):605-9. PubMed ID: 26031274
[TBL] [Abstract][Full Text] [Related]
3. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
[TBL] [Abstract][Full Text] [Related]
4. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
5. Higher Tinzaparin Dosing Is Needed to Achieve Target Anti-Xa Levels in Pediatric Cardiac Intensive Care Patients.
Roeleveld PP; van der Hoeven A; de Wilde RB; Eikenboom J; Smiers FJ; Bunker-Wiersma HE
Pediatr Crit Care Med; 2016 Mar; 17(3):203-9. PubMed ID: 26808621
[TBL] [Abstract][Full Text] [Related]
6. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
[TBL] [Abstract][Full Text] [Related]
8. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
Lin H; Faraklas I; Saffle J; Cochran A
J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin and anti-Xa targets in critically ill children: are we on target with our target?*.
Parker RI
Pediatr Crit Care Med; 2014 Sep; 15(7):679-81. PubMed ID: 25186327
[No Abstract] [Full Text] [Related]
10. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
[TBL] [Abstract][Full Text] [Related]
11. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
12. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
13. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
Kopelman TR; O'Neill PJ; Pieri PG; Salomone JP; Hall ST; Quan A; Wells JR; Pressman MS
Am J Surg; 2013 Dec; 206(6):911-5; discussion 915-6. PubMed ID: 24296098
[TBL] [Abstract][Full Text] [Related]
14. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
Israel EN; Thomas CA; Mastropietro CW
Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
[TBL] [Abstract][Full Text] [Related]
15. Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
Andrade-Campos MM; Montes-Limón AE; Fernandez-Mosteirin N; Salvador-Osuna C; Torres M; Lucia-Cuesta JF; Rubio-Felix D
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):194-8. PubMed ID: 23358201
[TBL] [Abstract][Full Text] [Related]
16. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
[TBL] [Abstract][Full Text] [Related]
17. Increased enoxaparin dosing is required for obese children.
Lewis TV; Johnson PN; Nebbia AM; Dunlap M
Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026
[TBL] [Abstract][Full Text] [Related]
18. Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis.
Farrar JE; Droege ME; Philpott CD; Mueller EW; Ernst NE; Makley AT; Deichstetter KM; Droege CA
J Surg Res; 2021 Aug; 264():425-434. PubMed ID: 33848842
[TBL] [Abstract][Full Text] [Related]
19. IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
Diab YA; Ramakrishnan K; Ferrell B; Chounoune R; Alfares FA; Endicott KM; Rooney S; Corcoran J; Zurakowski D; Berger JT; Shankar V; Nath DS
Pediatr Crit Care Med; 2017 May; 18(5):e207-e214. PubMed ID: 28296662
[TBL] [Abstract][Full Text] [Related]
20. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
Hicks JK; Shelton CM; Sahni JK; Christensen ML
Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
